SCM
CRBP icon

Stonepine Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Stonepine Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.99M Buy
425,000
+41,538
+11% +$393K 2.25% 14
2026
Q1 		$3.6M Sell
383,462
-6,454
-2% -$54.3K 1.44% 12
2025
Q4 		$3.17M Buy
+389,916
New +$4.81M 2.32% 9
2025
Q2 		– Sell
-35,000
Closed -$186K – 64
2025
Q1 		$186K Buy
+35,000
New +$309K 0.18% 52

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Stonepine Capital Management's CRBP Position: Q2 2026 in Review

Stonepine Capital Management increased its Corbus Pharmaceuticals (CRBP) stake by 11% in Q2 2026, buying an estimated $393K and bringing the position to 425,000 shares worth $3.99M. The position accounts for 2.25% of the portfolio, ranked #14.

Stonepine Capital Management first reported a position in CRBP in Q1 2025 and has held it in 4 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Stonepine Capital Management held 425,000 shares of Corbus Pharmaceuticals worth $3.99M as of Q2 2026.
  • Stonepine Capital Management bought 41,538 Corbus Pharmaceuticals shares in Q2 2026, an estimated $393K.
  • Corbus Pharmaceuticals made up 2.25% of Stonepine Capital Management's portfolio in Q2 2026, its #14 holding.
  • Stonepine Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.